Nonpharmacologic options for treating irritable bowel syndrome

Area of Science:

• Gastroenterology
• Microbiome research
• Dietary science

Background:

• Irritable bowel syndrome (IBS) is a prevalent chronic functional gastrointestinal disorder.
• Current IBS management often involves antimotility agents, laxatives, and antidepressants.
• The etiology of IBS is complex and multifactorial, lacking a clear organic cause.

Purpose of the Study:

• To review emerging therapeutic strategies for Irritable Bowel Syndrome (IBS).
• To explore novel interventions beyond conventional pharmacological treatments.
• To provide an overview of current research in IBS management.

Main Methods:

• Literature review of recent studies and clinical trials.
• Synthesis of evidence on probiotics, fecal microbiota transplant (FMT), low FODMAP diet, and cognitive behavioral therapy (CBT).
• Analysis of the potential mechanisms and efficacy of these newer approaches.

Main Results:

• Probiotics demonstrate potential in modulating gut microbiota and alleviating IBS symptoms.
• Fecal microbiota transplant (FMT) shows promise as a treatment option, though further research is needed.
• A low fermentable oligo-, di-, monosaccharides, and polyols (FODMAP) diet is effective for symptom management in a significant portion of IBS patients.
• Cognitive behavioral therapy (CBT) offers a non-pharmacological approach to manage IBS by addressing the brain-gut axis.

Conclusions:

• Emerging therapies including probiotics, FMT, low FODMAP diet, and CBT represent promising avenues for IBS management.
• These interventions target different aspects of IBS pathophysiology, offering personalized treatment options.
• Further research is warranted to optimize the application and understand the long-term efficacy of these novel IBS treatments.